Expert clinical framework report: Management of adverse events related to novel therapies for relapsed/refractory multiple myeloma (RRMM). Can Hematol Today [Internet]. 2022 Nov. 15 [cited 2026 Apr. 21];1(S11). Available from: https://canadianhematologytoday.com/article/view/30